AL 39324

Drug Profile

AL 39324

Alternative Names: AL-39,324; Receptor tyrosine kinase inhibitor - Alcon

Latest Information Update: 30 Jul 2015

Price : $50

At a glance

  • Originator Unknown
  • Developer Alcon
  • Class Eye disorder therapies
  • Mechanism of Action Receptor protein-tyrosine kinase antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Diabetic retinopathy
  • Discontinued Age-related macular degeneration

Most Recent Events

  • 01 Nov 2012 No development reported - Phase-I/II for Diabetic retinopathy in USA (Intravitreous)
  • 08 Apr 2011 Novartis completes acquisition of Alcon
  • 26 Aug 2010 Alcon has been acquired by Novartis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top